Infect Control Hosp Epidemiol by Hostler, Christopher J. et al.
Feasibility and Value of Developing a Regional Antibiogram for 
Community Hospitals
Christopher J. Hostler, MD, MPH1,2,3, Rebekah W. Moehring, MD, MPH1,2, Elizabeth S. 
Dodds Ashley, PharmD, MHS1,2, Melissa Johnson, PharmD1,2, Angelina Davis, PharmD, 
MS1,2, Sarah S. Lewis, MD, MPH1,2, Daniel J. Sexton, MD1,2, Deverick J. Anderson, MD, 
MPH1,2 CDC Prevention Epicenters Program
1.Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina
2.Duke University School of Medicine, Durham, North Carolina
3.Durham VA Health Care System, Durham, North Carolina
Abstract
OBJECTIVE.—To determine the feasibility and value of developing a regional antibiogram for 
community hospitals.
DESIGN.—Multicenter retrospective analysis of antibiograms.
SETTING AND PARTICIPANTS.—A total of 20 community hospitals in central and eastern 
North Carolina and south central Virginia participated in this study.
METHODS.—We combined antibiogram data from participating hospitals for 13 clinically 
relevant gram-negative pathogen–antibiotic combinations. From this combined antibiogram, we 
developed a regional antibiogram based on the mean susceptibilities of the combined data.
RESULTS.—We combined a total of 69,778 bacterial isolates across 13 clinically relevant gram-
negative pathogen–antibiotic combinations (median for each combination, 1100; range, 174–
27,428). Across all pathogen–antibiotic combinations, 69% of local susceptibility rates fell within 
1 SD of the regional mean susceptibility rate, and 97% of local susceptibilities fell within 2 SD of 
the regional mean susceptibility rate. No individual hospital had > 1 pathogen–antibiotic 
combination with a local susceptibility rate > 2 SD of the regional mean susceptibility rate. All 
hospitals’ local susceptibility rates were within 2 SD of the regional mean susceptibility rate for 
low-prevalence pathogens (<500 isolates cumulative for the region).
CONCLUSIONS.—Small community hospitals frequently cannot develop an accurate 
antibiogram due to a paucity of local data. A regional antibiogram is likely to provide clinically 
useful information to community hospitals for low-prevalence pathogens.
Antibiograms provide relevant clinical information for providers, infection preventionists, 
and antimicrobial stewardship programs (ASPs),1 most notably providing information about 
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the prevalence of resistant pathogens at an institution. To provide accurate information about 
pathogen susceptibilities, however, antibiograms must have sufficient numbers of isolates for 
individual pathogens. In fact, the Clinical and Laboratory Standards Institute (CLSI) M39-
A2 guidelines require that only pathogens with at least 30 isolates be included in an 
antibiogram to achieve an accuracy level of  ߡ5%  for empiric susceptibilities.2
Unfortunately, community hospitals typically do not follow CLSI guidelines for antibiogram 
development.3 A key reason is that microbiology laboratories in most community hospitals 
do not isolate the required number of individual pathogens to develop a reliable annual 
antibiogram, which can leave providers without adequate information to make appropriate 
empiric therapy decisions.
In small facilities where the number of clinical isolates is inadequate to prepare an 
antibiogram, aggregating data from multiple hospitals into a single regional antibiogram 
may be a practical alternative.4 Previous studies have compiled “geographically focused” 
antibiograms including data from both tertiary-care and community hospitals. Unfortunately, 
the results of such efforts typically involve more isolates from tertiary-care centers, skewing 
susceptibility patterns toward facilities with more intensive care unit (ICU) beds and higher 
local prevalence of antimicrobial-resistant pathogens.5,6 As a result, physicians in 
community hospitals using this type of regional antibiogram may overestimate the 
prevalence of multidrug-resistant organisms (MDROs).
We aggregated antimicrobial susceptibility data from multiple community hospitals within a 
single geographic region to provide physicians working in small community hospitals with 
clinically useful data on regional susceptibility patterns. The objectives of this study were 
(1) to develop a regional antibiogram and (2) to assess its utility by comparing rates reported 
at individual hospitals to the regional mean.
METHODS
The Duke Infection Control Outreach Network (DICON) is a collaborative network of 
community hospitals in the southeastern United States that shares surveillance data.7 We 
combined antibiogram data for 13 clinically relevant combinations of bacterial pathogens 
and antibiotics (Table 1) collected during calendar year 2012 from 20 DICON hospitals 
located in central and eastern North Carolina and south-central Virginia. Each hospital has 
its own microbiology lab and developed its own antibiogram. Among 20 local hospitals, 6 
stratified isolates by location (inpatient vs outpatient vs ICU) or source (urine vs non-urine) 
when preparing their local antibiogram; the remainder did not. For the purposes of this 
study, we included all isolates from all locations and sources in the aggregate regional 
antibiogram, even if there were fewer than 30 isolates from an individual facility.
We calculated regional mean susceptibility (standard deviation, SD) by dividing the total 
number of susceptible organisms for each pathogen–antibiotic combination across all 20 
hospitals by the total number of tested organisms for that pathogen–antibiotic combination. 
We then created modified box-and-whisker plots for each pathogen–antibiotic combination 
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to demonstrate each hospital-specific susceptibility in comparison to the regional mean 
susceptibility (Figure 1).
We then determined the number of hospitals with susceptibilities within 1 or 2 SD of the 
regional mean to determine how well the regional mean represented the hospitals. We 
plotted the distance between hospital-specific susceptibilities and the regional mean 
susceptibilities by percentage of isolates contributed to the regional antibiogram for each 
pathogen–antibiotic combination to demonstrate the effect of number of pathogens isolated 
on the difference between local and regional mean susceptibilities. We examined the number 
of isolates contributed by hospitals based on their bed capacity as well. Hospitals with ≥250 
beds were considered “large” community hospitals; hospitals with <250 beds were 
considered “small” community hospitals.
For instance, to develop the regional mean susceptibility of Escherichia coli to trimethoprim-
sulfamethoxazole, we calculated the total number of E. coli cultures susceptible to 
trimethoprim-sulfamethoxazole across all 20 hospitals and divided by the total number of E. 
coli cultures. We then compared each hospital-specific susceptibility to the regional mean 
susceptibility to determine whether the hospital-specific susceptibility was within 1 and/or 2 
SD of the regional susceptibility. Finally, we compared the difference between each hospital-
specific and regional mean susceptibilities based on how many E. coli isolates and 
corresponding trimethoprim-sulfamethoxazole susceptibilities they contributed to the 
regional antibiogram.
RESULTS
We combined a total of 69,778 bacterial isolates across the 13 clinically relevant gram-
negative pathogen–antibiotic combinations (median for each combination, 1,100; range, 
174–27,428) to develop our regional antibiogram. For each pathogen–antibiotic 
combination, we report the number of isolates, number of hospitals reporting, regional mean 
susceptibility, and number of hospitals with susceptibility within 1 and 2 SD of the regional 
mean susceptibility (Table 1).
Escherichia coli (range, 45–4,695 isolates) was the most prevalent pathogen included in the 
analysis; all 20 hospitals reported > 30 isolates in accordance with CLSI guidelines. 
Stenotrophomonas maltophilia was the least frequently reported pathogen, with only 7 
hospitals reporting susceptibility data for this pathogen, and only 2 hospitals had > 30 
isolates (range, 14–35). Across all pathogen–antibiotic combinations, 69% of hospital-
specific susceptibilities fell within 1 SD of the regional mean susceptibility rate, and 97% of 
hospital-specific susceptibilities fell within 2 SD of the regional mean susceptibility rate. No 
individual hospital had > 1 pathogen–antibiotic combination susceptibility > 2 SD from the 
regional mean susceptibility rate. All hospital-specific susceptibilities were within 2 SD of 
the regional mean susceptibility rate for low prevalence pathogens (<500 isolates cumulative 
for the region).
Our network has a significant degree of variation in bed sizes, but the contribution of each 
hospital was distributed evenly. The 7 large community hospitals contributed 49% of the 
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isolates for this regional antibiogram. The remaining 13 small community hospitals 
contributed 51% of the isolates.
In total, we analyzed 178 hospital-specific pathogen–antibiotic susceptibility combinations 
for this study. Overall, 138 (77.5%) hospital-specific combinations comprised <10% of the 
isolates for their respective pathogen–antibiotic combinations, and 40 (22.5%) hospital-
specific combinations represented ≥10% of the total isolates for each respective pathogen–
antibiotic combination.
Hospitals contributing fewer isolates were not more likely to have hospital-specific 
susceptibility rates > 1 SD from the regional mean. Of the 178 hospital-specific pathogen–
antibiotic susceptibility combinations analyzed in this study, 56 (31.5%) were > 1 SD from 
the regional mean susceptibility for their respective pathogen–antibiotic combinations. Of 
the 138 susceptibility combinations that comprised <10% of the isolates contributed to the 
regional mean, 44 (31.8%) were > 1 SD from the regional mean susceptibility. Of the 40 
susceptibility combinations that comprised ≥ 10% of the isolates contributed to the regional 
mean, 12 (30.0%) were > 1 SD from the regional mean susceptibility. The difference 
between hospital-specific susceptibilities and the regional means was unchanged regardless 
of the percentage of isolates contributed by that hospital (Figure 2).
Hospital-specific susceptibility combinations that appeared to be outliers could not be 
predicted by whether a hospital followed CLSI reporting guidelines. Of the 56 hospital-
specific pathogen–antibiotic susceptibility combinations that were > 1 SD from the regional 
mean susceptibility, only 9 (16%) came from hospitals reporting <30 isolates for that 
pathogen/antibiotic combination.
DISCUSSION
Our study showed that susceptibility data from a large number of geographically co-located 
community hospitals can be combined to form a meaningful regional antibiogram. Our 
regional antibiogram for high-prevalence pathogens such as E. coli demonstrated that 
susceptibility results in 95% of hospitals are clustered around the regional mean (within 2 
SD), indicating that susceptibility rates for this common pathogen did not vary widely across 
the geographic region. A regional approach may be most advantageous, however, for 
infrequently isolated pathogens. All hospital-specific susceptibilities were clustered around 
the regional means for these pathogens with fewer than 30 local isolates.
Hospitals that contributed few isolates to the regional antibiogram did not have significantly 
greater differences between hospital-specific susceptibilities and the regional mean 
susceptibility compared to hospitals that contributed most isolates. This finding is important 
because it reflects the relative homogeneity of the data by hospital contribution.
While underestimating a pathogen’s susceptibility to an antibiotic may change empiric 
therapy choices, overestimating a pathogen’s susceptibility to an antibiotic has the potential 
to harm patients. The overall low percentage of outliers indicates that the likelihood of 
overestimating the susceptibility for a pathogen–antibiotic combination in a clinically 
significant way when using regional susceptibility is low. However, hospitals may choose to 
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use their local susceptibility rates in place of the regional susceptibility rates if their local 
susceptibility rates appear significantly lower than the regional mean for frequently isolated 
pathogens.
Importantly, no hospital-specific susceptibility for a pathogen–antibiotic combination was > 
2 SD of the regional mean susceptibility. Indeed, resistance patterns among such low-
prevalence pathogens did not vary significantly across our geographic region.
Small community hospitals that have too few isolates of important pathogens to allow them 
to prepare a meaningful antibiogram are most likely to benefit from a regional antibiogram. 
With a regional antibiogram, providers will have useful adjunctive information to assist in 
choosing appropriate empiric therapy.
This study has several limitations. We used pooled mean susceptibility rates; thus, 
susceptibility data from larger hospitals may have had a disproportionately greater influence 
on the regional mean susceptibility rates. Although susceptibility testing was standardized in 
accordance with CLSI guidelines, antibiogram reporting methods were not standardized 
across hospitals. However, failure to observe CLSI reporting guidelines is well documented 
in the literature and is not unique to our cohort of community hospitals.3,8,9
Our future directions include disseminating this regional antibiogram to hospitals in our 
network and then assessing how it is used by community hospitals. We also plan to 
emphasize that regional susceptibility rates should not replace local data when such 
information is available. Finally, the likelihood of receiving regionally appropriate empiric 
therapy can be calculated before and after dissemination of the antibiogram in hospitals with 
an absence of locally useful data for specific pathogen–antibiotic combinations.
Antibiograms remain an important tool for aiding clinical decisions related to empiric 
antimicrobial treatment, but they have limitations. Many small community hospitals struggle 
to develop antibiograms due to the low prevalence of some pathogens.3 We believe a 
regional antibiogram can overcome such limitations and thus provide clinically useful 
susceptibility data on low-prevalence pathogens to clinicians practicing in these settings.
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FIGURE 1. 
Hospital versus regional susceptibilities for Escherichia coli and fluoroquinolones.
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FIGURE 2. 
Distribution of hospital-specific difference from regional mean susceptibility compared to 
percentage of isolates contributed to the regional antibiogram.
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